Puma Leaps After Hours, FDA Delays Decision On Merck's Drug, ADMP Optimistic

Shares of Puma Biotechnology Inc. (PBYI) were up over 20% in extended trading on Thursday, following encouraging interim 5-year invasive disease free survival results from the company's phase III trial of PB272 (Neratinib) in extended adjuvant HER2-positive early stage breast cancer.

from RTT - Biotech http://ift.tt/2a0je4N
via IFTTT